CSI Market
Sign In | Register

Perspective Therapeutics Inc (CATX) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access CATX quarterly Cash Flow →
From Perspective Therapeutics Inc through Jun 30 2021, changes in Dec 31 2025's operating cash flow provide insight into underlying business performance trends.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Jun 30 2022) (Jun 30 2021)
Operating Activities
Income-103.12
Depreciation & amortization3.25
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue-1.40
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)10.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation8.97
Income (Loss) from Equity Method Investments0.00
Foreign Currency Transaction Gain (Loss), before Tax, Total0.25
Gain Loss On Change In A R O Estimate-
Increase Decrease In Accrued Protocol Expense-
Increase Decrease In Accrued Payroll And Related Taxes-
Noncash Expense Lease-
Accrued Interest On Short Term Investments-
Asset Retirement Obligation Revision Of Estimate-
Net Accretion Of Discounts On Available For Sale Securities-
Net Accretion Of Discounts On Available- For- Sale Securities-2.72
Increase Decrease In Inventory Related To Discontinued Operations-
Income taxes-0.79
Losses/ -gains on Investments net0.00
Accounts Receivable1.98
Increase (Decrease) in Accounts Payable and Accrued Liabilities0.15
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.62
Other Working Capital0.33
Other Noncash Income (Expense)0.01
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-82.48
Investing Activities
Capital Expenditures-12.88
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Available-for-sale Securities173.95
Payments to Acquire Available-for-sale Securities, Debt-119.84
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Cash Acquired from Acquisition0.00
Payments to Acquire Equity Method Investments0.00
Sale of businesses0.00
Accounts payable0.00
Payments to Acquire Notes Receivable0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities41.23
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments-0.05
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.37
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-61.58
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations61.58
Restricted Cash And Cash Equivalents Noncurrent-
Proceeds From Prefunded Warrants Net-
Proceeds From Issuance Of Common Stock And Prefunded Warrants Net-
Proceeds From Issuance Of Prefunded Warrants Net-
Proceeds From Sales Of Common Stock And Pre- Funded Warrants Net-
Proceeds From Issuance Of Common Stock Pursuant To At- The- Market Net9.99
Proceeds From Issuance Of Common Stock And Pre- Funded Warrants Net-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities10.31
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-95.37
Total Cash Flow-30.95
4 historic quarters locked

Sign in to unlock the full Perspective Therapeutics Inc cash flow history.

Sign In Create Free Account

About Perspective Therapeutics Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0000728387-26-000004

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License